GSK plc announced that Japan approved its RSV vaccine, Arexvy, for adults aged 50-59 at increased risk due to health conditions, expanding its application from the previous approval for those aged 60 and older. This approval reflects GSK's commitment to protecting vulnerable populations from severe RSV infections, based on successful trial results as of November 22, 2024.